AstraZeneca’s (AZN) Buy Rating Reaffirmed at Shore Capital

Shore Capital reiterated their buy rating on shares of AstraZeneca (LON:AZN) in a report issued on Tuesday morning, MarketBeat Ratings reports. Shore Capital currently has a £145 price objective on the biopharmaceutical company’s stock.

Other research analysts also recently issued research reports about the company. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a £110 price objective on shares of AstraZeneca in a report on Wednesday, July 30th. Berenberg Bank reiterated a “buy” rating and issued a £142 price objective on shares of AstraZeneca in a report on Monday, September 1st. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of £134.25.

AstraZeneca Trading Up 0.4%

LON AZN opened at £127.80 on Tuesday. The stock’s 50-day simple moving average is £116.55 and its two-hundred day simple moving average is £109.12. AstraZeneca has a twelve month low of GBX 9,573.51 and a twelve month high of £128.66. The company has a quick ratio of 0.59, a current ratio of 0.93 and a debt-to-equity ratio of 73.83. The company has a market capitalization of £198.12 billion, a price-to-earnings ratio of 2,406.78, a PEG ratio of 0.86 and a beta of 0.17.

Insider Activity

In related news, insider Aradhana Sarin sold 9,563 shares of the firm’s stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of £115.12, for a total value of £1,100,892.56. 0.14% of the stock is owned by insiders.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.